THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen makes a substantial contribution to the efficiency and effectiveness of the translational process. TD2 was formed in 2003 as a subsidiary of TGen.
IMAGING ENDPOINTS is a full-service imaging contract research organization providing services to the pharmaceutical and medical device industries to accelerate their national and international oncology clinical trials. Extensive expertise in cancer imaging allows Imaging Endpoints to perform qualitative and quantitative assessments of both anatomic and physiologic/metabolic imaging modalities in order to evaluate the effectiveness of new therapeutics.
STUDYLOG provides animal study management solutions to commercial and academic research organizations, enabling organizations to efficiently manage studies and data within a searchable and accessible framework. Organizations can now centrally store and index the institutional knowledge that usually resides in notebooks and the memories of individual researchers.
MEDICAL PROGNOSIS INSTITUTE (MPI) was founded to improve the efficacy of cancer drugs through its multi-biomarker technology, the Drug Response Predictor (DRP). DRP is a validated, unique multi-biomarker built on an algorithm from big data and derived from human cancer tissue. DRP can be added to and will strengthen existing tools within the drug development field.